Colhoun Helen M, Taskinen Marja-Riitta, Otvos James D, Van Den Berg Paul, O'Connor John, Van Tol Arie
Royal Free and University College London Medical School, London, U.K.
Diabetes. 2002 Nov;51(11):3300-5. doi: 10.2337/diabetes.51.11.3300.
Patients with type 1 diabetes have greatly increased phospholipid transfer protein (PLTP) activity and have an altered HDL subclass distribution. In 195 patients with type 1 diabetes and in 194 men and women aged 30-55 years, we examined the relationship of PLTP activity to HDL and examined whether PLTP activity contributes to differences in HDL found in type 1 diabetes. PLTP activity was measured using an exogenous substrate assay. Average HDL particle size and HDL subclasses were measured using nuclear magnetic resonance spectroscopy. Apolipoprotein AI (apoAI) and apoAII were measured by immunoturbidimetry. The amount of apoAI present in LpAI was measured using a differential electroimmunoassay, and the amount of apoAI in LpAIAII was inferred from the apoAI and LpAI data. Higher PLTP activity was associated with more large HDL (P < 0.001) and less small HDL (P < 0.01), more apoAI and apoAII (both at P < 0.001), and more apoAI in both LpAI and LpAIAII (P = 0.02 and P < 0.001, respectively). These associations were independent of other lipids and enzyme activities. Adjusting for PLTP activity halved the difference between subjects with and without diabetes in apoA1 (from 10.1 mg/dl higher in subjects with diabetes to 4.6 mg/dl higher) and large HDL (2.4 micro mol/l higher to 1.2 micro mol/l higher) and reduced the difference in HDL size (from 0.31 nm higher to 0.26 nm higher). PLTP activity was also positively associated with apoB, total VLDL and LDL particle number, and IDL level in subjects with diabetes. These data support the idea that PLTP is a major factor in HDL conversion and remodeling in humans and that higher PLTP activity makes an important contribution to the higher apoAI levels and altered HDL subclass distribution in type 1 diabetes. They also support a role for PLTP in the metabolism of apoB-containing lipoproteins.
1型糖尿病患者的磷脂转运蛋白(PLTP)活性大幅增加,高密度脂蛋白(HDL)亚类分布也发生改变。在195例1型糖尿病患者以及194名年龄在30至55岁的男性和女性中,我们研究了PLTP活性与HDL的关系,并探讨PLTP活性是否导致1型糖尿病患者HDL的差异。采用外源性底物分析法测定PLTP活性。使用核磁共振波谱法测量平均HDL颗粒大小和HDL亚类。通过免疫比浊法测定载脂蛋白AI(apoAI)和载脂蛋白AII(apoAII)。使用差分电免疫分析法测量LpAI中apoAI的含量,并根据apoAI和LpAI数据推断LpAIAII中apoAI的含量。较高的PLTP活性与更多的大HDL(P < 0.001)和更少的小HDL(P < 0.01)、更多的apoAI和apoAII(均P < 0.001)以及LpAI和LpAIAII中更多的apoAI相关(分别为P = 0.02和P < 0.001)。这些关联独立于其他脂质和酶活性。校正PLTP活性后,糖尿病患者与非糖尿病患者之间apoA1的差异减半(从糖尿病患者高10.1 mg/dl降至高4.6 mg/dl),大HDL的差异也减半(从高2.4 μmol/l降至高1.2 μmol/l),HDL大小差异减小(从高0.31 nm降至高0.26 nm)。在糖尿病患者中,PLTP活性还与apoB、总极低密度脂蛋白(VLDL)和低密度脂蛋白(LDL)颗粒数以及中间密度脂蛋白(IDL)水平呈正相关。这些数据支持以下观点:PLTP是人类HDL转化和重塑的主要因素,较高的PLTP活性对1型糖尿病患者较高的apoAI水平和HDL亚类分布改变起重要作用。它们还支持PLTP在含apoB脂蛋白代谢中的作用。